home / stock / allo / allo quote
Last: | $3.04 |
---|---|
Change Percent: | 0.0% |
Open: | $3.37 |
Close: | $3.04 |
High: | $3.42 |
Low: | $3.03 |
Volume: | 2,107,578 |
Last Trade Date Time: | 04/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.04 | $3.37 | $3.04 | $3.42 | $3.03 | 2,107,578 | 04-24-2024 |
$3.37 | $3.41 | $3.37 | $3.53 | $3.36 | 1,606,756 | 04-23-2024 |
$3.4 | $3.49 | $3.4 | $3.63 | $3.38 | 1,789,993 | 04-22-2024 |
$3.47 | $3.45 | $3.47 | $3.555 | $3.38 | 2,013,218 | 04-19-2024 |
$3.46 | $3.52 | $3.46 | $3.56 | $3.45 | 1,245,819 | 04-18-2024 |
$3.51 | $3.57 | $3.51 | $3.58 | $3.455 | 2,507,828 | 04-17-2024 |
$3.5 | $3.5 | $3.5 | $3.555 | $3.395 | 1,388,064 | 04-16-2024 |
$3.55 | $3.86 | $3.55 | $3.88 | $3.535 | 1,592,742 | 04-15-2024 |
$3.8 | $3.98 | $3.8 | $4.0062 | $3.74 | 2,882,301 | 04-12-2024 |
$3.99 | $4.14 | $3.99 | $4.21 | $3.99 | 2,153,258 | 04-11-2024 |
$4.07 | $3.91 | $4.07 | $4.25 | $3.87 | 2,326,913 | 04-10-2024 |
$4.11 | $3.99 | $4.11 | $4.11 | $3.93 | 1,368,742 | 04-09-2024 |
$3.98 | $3.96 | $3.98 | $4.04 | $3.895 | 1,129,476 | 04-08-2024 |
$3.96 | $4.02 | $3.96 | $4.06 | $3.91 | 939,016 | 04-05-2024 |
$4.05 | $4.13 | $4.05 | $4.3 | $4.03 | 1,683,614 | 04-04-2024 |
$4.09 | $4.04 | $4.09 | $4.105 | $3.95 | 1,302,318 | 04-03-2024 |
$4.07 | $4.26 | $4.07 | $4.26 | $4.06 | 1,544,522 | 04-02-2024 |
$4.38 | $4.43 | $4.38 | $4.45 | $4.285 | 1,290,451 | 04-01-2024 |
$4.47 | $4.41 | $4.47 | $4.575 | $4.41 | 1,377,673 | 03-29-2024 |
$4.47 | $4.41 | $4.47 | $4.575 | $4.41 | 1,377,673 | 03-28-2024 |
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology compan...
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participat...
Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) : Start-Up Activities Underway; Enrollment to Begin Mid-2024 Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Dat...